Related references
Note: Only part of the references are listed.TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity
Xiaojie Yu et al.
COMMUNICATIONS BIOLOGY (2021)
On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation
Joshua M. Sopp et al.
COMMUNICATIONS BIOLOGY (2021)
Single B cell technologies for monoclonal antibody discovery
Alessandro Pedrioli et al.
TRENDS IN IMMUNOLOGY (2021)
FDA approves 100th monoclonal antibody product
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2021)
Computational design of a synthetic PD-1 agonist
M. Bryana Cassie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors
Adam P. Curnock et al.
JCI INSIGHT (2021)
Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease
David Gate et al.
NATURE (2020)
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity
Xiaojie Yu et al.
CANCER CELL (2020)
Immune receptor inhibition through enforced phosphatase recruitment
Ricardo A. Fernandes et al.
NATURE (2020)
Revisiting the PD-1 pathway
Nikolaos Patsoukis et al.
SCIENCE ADVANCES (2020)
Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates
Charlotte Viant et al.
CELL (2020)
Development of therapeutic antibodies for the treatment of diseases
Ruei-Min Lu et al.
JOURNAL OF BIOMEDICAL SCIENCE (2020)
A simplified workflow for monoclonal antibody sequencing
Lena Meyer et al.
PLOS ONE (2019)
Trends in therapeutic antibody affinity maturation: From in-vitro towards next-generation sequencing approaches
Maryam Tabasinezhad et al.
IMMUNOLOGY LETTERS (2019)
Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells
Kankana Bardhan et al.
SCIENTIFIC REPORTS (2019)
Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies
Xiaojie Yu et al.
CANCER CELL (2018)
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2018)
The promise and challenges of immune agonist antibody development in cancer
Patrick A. Mayes et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
S. Michael Chin et al.
NATURE COMMUNICATIONS (2018)
Immune Checkpoints as Therapeutic Targets in Autoimmunity
Christopher Paluch et al.
FRONTIERS IN IMMUNOLOGY (2018)
Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor α
Federica Sallusto et al.
JOURNAL OF IMMUNOLOGY (2018)
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Cariad Chester et al.
BLOOD (2018)
Monoclonal Antibodies: A Review
Surjit Singh et al.
CURRENT CLINICAL PHARMACOLOGY (2018)
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
Rony Dahan et al.
CANCER CELL (2016)
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Ju Yeon Lee et al.
NATURE COMMUNICATIONS (2016)
Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo
Ali Roghanian et al.
CANCER CELL (2015)
Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies
Ann L. White et al.
CANCER CELL (2015)
Principles of antibody-mediated TNF receptor activation
H. Wajant
CELL DEATH AND DIFFERENTIATION (2015)
Stock-based detection of protein oligomeric states in jsPISA
Eugene Krissinel
NUCLEIC ACIDS RESEARCH (2015)
A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency
M. Chodorge et al.
CELL DEATH AND DIFFERENTIATION (2012)
Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors
Stephen I. Rudnick et al.
CANCER RESEARCH (2011)
Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
Ann L. White et al.
JOURNAL OF IMMUNOLOGY (2011)
The role of CD40 and CD154/CD40L in dendritic cells
Daphne Y. Ma et al.
SEMINARS IN IMMUNOLOGY (2009)
Inference of macromolecular assemblies from crystalline state
Evgeny Krissinel et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
JM Chemnitz et al.
JOURNAL OF IMMUNOLOGY (2004)
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin
CD Austin et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells
CL Ahonen et al.
NATURE IMMUNOLOGY (2002)